CME/CE

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.

Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they:

• Breakdown how to recognize key inflammatory patterns.
• Discuss the burden of illness and goals of treatment
• Interpret clinical trial data on biologic treatments.
• Apply a collaborative care approach to improve patient outcomes.

Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings.

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Marianne Silkjaer Nielsen. Not only is Ms. Nielsen the mother of a girl who lives with immune complex-MPGN, but she’s also the founder of CompCure, a not-for-profit association that is dedicated to improving outcomes in patients with C3G and immune complex-MPGN.

Together, their conversation will cover:

• The Diagnostic Journey: Rare diseases often have a long diagnostic journey. A specialized pathologist is often needed to identify the disease, and many patients are not diagnosed until they have severe symptoms.
  
• Therapeutic Challenges: The realization that there is no cure or disease-modifying therapy can be devastating. Furthermore, the lack of widespread experience in these rare diseases among physicians, coupled with a lack of long-term evidence, can lead to suboptimal care and poor outcomes.
  
• Impact of Delayed Treatment: Also discussed is the importance of screening programs for kidney diseases and access to targeted therapies—which until now, were not available—before critical illness sets in.
  
• Future Outlook and Advocacy: